title: Secukinumab.
abstract: Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation/medication use evaluation (DUE/MUE) is also provided each month. With a subscription, the monographs are sent in print and are also available on-line. Monographs can be customized to meet the needs of a facility. A drug class review is now published monthly with The Formulary Monograph Service. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. For more information about The Formulary Monograph Service, call The Formulary at 800-322-4349. The September 2015 monograph topics are cangrelor, lumacaftor/ivacaftor, brexpiprazole, talimogene laherparepvec, and lesinurad. The Safety MUE is on cangrelor.
authors.affiliation: Founder and Contributing Editor, The Formulary.
authors.forename: Dennis J
authors.initials: DJ
authors.lastname: Cada
authors.affiliation: Director, Drug Information Center, and Professor of Pharmacy Practice, College of Pharmacy, Washington State University Spokane.
authors.forename: Danial E
authors.initials: DE
authors.lastname: Baker
authors.affiliation: Clinical Assistant Professor, College of Pharmacy, Washington State University , Spokane.
authors.forename: Shannon G
authors.initials: SG
authors.lastname: Panther
authors.affiliation: Drug Information Resident, College of Pharmacy, Washington State University Spokane . The authors indicate no relationships that could be perceived as a conflict of interest.
authors.forename: Kyle Ingram
authors.initials: KI
authors.lastname: PharmD
references.citation: J Dermatol. 2014 Dec;41(12 ):1039-46
references.pmid: 25354738
references.citation: Ann Rheum Dis. 2014 Feb;73(2):349-56
references.pmid: 23361084
references.citation: N Engl J Med. 2014 Jul 24;371(4):326-38
references.pmid: 25007392
references.citation: Br J Dermatol. 2015 Feb;172(2):484-93
references.pmid: 25132411
references.citation: Ann Rheum Dis. 2013 Jun;72(6):863-9
references.pmid: 22730366
references.citation: Eur J Dermatol. 2014 Sep-Oct;24(5):523-32
references.pmid: 25115238
references.citation: Clin Cosmet Investig Dermatol. 2014 Sep 15;7:251-9
references.pmid: 25246805
references.citation: Health Qual Life Outcomes. 2014 Mar 05;12:31
references.pmid: 24597620
references.citation: Ann Rheum Dis. 2013 Apr;72 Suppl 2:ii116-23
references.pmid: 23253932
references.citation: Arch Dermatol. 2012 Jan;148(1):95-102
references.pmid: 22250239
references.citation: Dermatol Ther (Heidelb). 2014 Jun;4(1):1-9
references.pmid: 24452484
references.citation: Br J Dermatol. 2013 Feb;168(2):402-11
references.pmid: 23362969
references.citation: J Cutan Med Surg. 2014 May-Jun;18(3):156-69
references.pmid: 24800703
references.citation: Clin Vaccine Immunol. 2012 Oct;19(10):1597-602
references.pmid: 22875601
references.citation: Dermatol Online J. 2014 Aug 17;20(8):null
references.pmid: 25148272
references.citation: Curr Opin Rheumatol. 2015 Mar;27(2):127-33
references.pmid: 25599143
references.citation: J Eur Acad Dermatol Venereol. 2014 Dec;28(12):1670-5
references.pmid: 24393602
references.citation: Br J Dermatol. 2012 Oct;167(4):717-24
references.pmid: 22716185
references.citation: Lancet. 2013 Nov 23;382(9906):1705-13
references.pmid: 24035250
references.citation: Ophthalmology. 2015 May;122(5):939-48
references.pmid: 25638011
references.citation: Br J Dermatol. 2013 Feb;168(2):412-21
references.pmid: 23106107
references.citation: J Eur Acad Dermatol Venereol. 2015 Jun;29(6):1082-90
references.pmid: 25243910